The relationship between serum tumor abnormal protein and mean platelet volume/lymphocyte ratio and the prognosis of patients with primary liver cancer undergoing laparoscopic hepatectomy

Abstract

Abstract: Objective To explore the relationship between serum tumor abnormal protein (TAP), mean platelet volume/lymphocyte ratio (MPVLR) and prognosis of patients with primary liver cancer (PLC) after laparoscopic hepatectomy.Methods Eight-five patients with PLC were enrolled in our hospital between January 2020 and September 2022. All patients underwent laparoscopic hepatectomy. The levels of TAP and MPVLR were detected before operation. The patients were followed up for 1 year after surgery to observe tumor recurrence, metastasis and death, and were divided into a poor prognosis group and a good prognosis group. Univariate and multivariate binary Logistic regression methods were used to analyze the influencing factors of prognosis in patients with PLC undergoing laparoscopic hepatectomy. The area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the predictive efficacy of serum TAP and MPVLR for the prognosis of patients.Results The incidence of poor prognosis in patients with PLC undergoing laparoscopic hepatectomy was 27.06% (23/85). The proportion of tumor diameter ≥3 cm, the proportion of CNLC stage Ⅲa, the proportion of multiple tumor numbers, TAP and MPVLR levels were 73.9%, 60.9%, 65.2%, (187.8±37.5) μm², and (7.7±1.93) in the poor prognosis group, respectively, which were higher than those of 37.1%, 27.4%, 32.3%, (139.2±27.8) μm², and (4.1±1.1) in the good prognosis group (P<0.05). Multivariate analysis showed that CNLC stage (OR=6.62), TAP (OR=5.39) and MPVLR (OR=3.85) were independent risk factors for the patients' prognosis (P<0.05). ROC curve analysis showed that the sensitivity, specificity and AUC of TAP, MPVLR and their combination in evaluating the prognosis of patients with PLC undergoing laparoscopic hepatectomy were 0.78, 0.74 and 0.87, 0.76, 0.74 and 0.92, 0.82, 0.80 and 0.91, respectively.Conclusion Serum TAP and MPVLR are independent risk factors for poor prognosis in patients with PLC undergoing laparoscopic hepatectomy. TAP combined with MPVLR has a better efficacy in evaluating the patients' prognosis.

Key words: Primary liver cancer, Laparoscopic hepatectomy, Tumor abnormal protein, Mean platelet volume/lymphocyte ratio, Assessment of prognosis

ZHANG Bei-ke, FAN Yong-gang, ZHANG Ying-nan, YAO Guo-liang. The relationship between serum tumor abnormal protein and mean platelet volume/lymphocyte ratio and the prognosis of patients with primary liver cancer undergoing laparoscopic hepatectomy[J]. Chinese Hepatolgy, 2024, 29(12): 1489-1492.

References

[1] Yanagaki M, Haruki K, Yasuda J, et al. The significance of the rapid turnover protein score as a predictor of the long-term outcomes in hepatocellular carcinoma after hepatic resection[J]. Ann Surg Oncol, 2021,28(13):8130-8139.
[2] Zhang J, Wang T, Xu L, et al. Thrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: A propensity score matching analysis[J]. Asian J Surg, 2021,44(1):423-424.
[3] Sun T, Wang X, Cao L, et al. Laparoscopic liver resection for primary liver cancers originating in the paracaval portion of the caudate lobe: a preliminary retrospective analysis with 31 patients[J]. Updates Surg, 2022,74(2):547-555.
[4] Tong H, Dan B, Dai H, et al. Clinical application of serum tumor abnormal protein combined with tumor markers in lung cancer patients[J]. Future Oncol, 2022,18(11):1357-1369.
[5] Song Y, Tian J, Yang L, et al. Prognostic value of preoperative platelet-related parameters and plasma fibrinogen in patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor[J]. Future Oncol, 2022,18(26):2933-2942.
[6] Chiang MH, Tsai KY, Chen HA, et al. Comparison of surgical outcomes for laparoscopic liver resection of large hepatocellular carcinomas: a retrospective observation from single-center experience[J]. Asian J Surg, 2021,44(11):1376-1382.
[7] Goh BKP, Syn N, Koh YX, et al. Comparison between short and long-term outcomes after minimally invasive versus open primary liver resections for hepatocellular carcinoma: a 1:1 matched analysis[J]. J Surg Oncol, 2021,124(4):560-571.
[8] 胡勇军, 汪磊, 刘宁, 等. 间歇性全入肝血流阻断与区域性入肝血流阻断腹腔镜肝切除术治疗原发性肝癌患者术后恢复研究. 实用肝脏病杂志, 2022,25(3):411-414.
[9] Cai H, Li W, Zhang Y, et al. Preoperative tumor abnormal protein is a promising biomarker for predicting hepatocellular carcinoma oncological outcome following curative resection[J]. J Cancer Res Ther, 2022,18(7):2021-2026.
[10] Guan Y, Yin S, Liang C. Clinical value of prostate-specific antigen combined with tumor abnormal protein (TAP) in the diagnosis of prostate puncture[J]. Transl Cancer Res, 2020,9(1):58-64.
[11] 周新玲,王敏,荆信勇. 子宫内膜细胞学联合血清TAP检测对子宫内膜癌初筛价值[J]. 中华肿瘤防治杂志,2019,26(12):827-830.
[12] Zyczkowski M, Kaletka Z, Rajwa P, et al. Mean platelet volume-to-lymphocyte ratio: a novel biomarker associated with overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy[J]. Int Urol Nephrol, 2020,52(5):885-891.
[13] Sökmen FC, Ulucaköy C. Diagnostic and prognostic role of mean platelet volume and mean platelet volume/platelet ratio in patients with primary malignant bone tumor[J]. Jt Dis Relat Surg, 2021,32(1):198-203.
[14] Jung M, Lee JA, Yoo SY, et al. Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas[J]. Mod Pathol, 2022,35(12):2011-2022.

[1]	DONG Yan-bing, NIU Meng, LUO Yue-bin, WEN Ting-liang. Clinical study of Sintilimab combined targeted therapy for intermediate and advanced primary liver cancer [J]. Chinese Hepatolgy, 2024, 29(9): 1068-1073.
[2]	CHEN Yan-xia, A Ni, XU Xuan, BAI Rong, LIU Xiao-zhi. Correlation analysis of enhanced MRI multimodal parameters and liver function grading in patients with primary liver cancer [J]. Chinese Hepatolgy, 2024, 29(6): 667-670.
[3]	JIANG Shi-wu, PENG Xiao-yan, CHEN Jun-yuan, FENG Fei-yao, LIU Mei-ling. The therapeutic effect of transcatheter arterial chemoembolization combined with toripalimab in 88 patients with advanced primary liver cancer [J]. Chinese Hepatolgy, 2024, 29(6): 676-680.
[4]	HAO Yuan-yuan, WANG Jun, XU Da-chao. The value of contrast-enhanced ultrasound in evaluating microwave ablation therapy for patients with special site primary liver cancer [J]. Chinese Hepatolgy, 2024, 29(5): 526-529.
[5]	SHU Jia-ju, YE Xi-rong. An observation study on the therapeutic efficacy of ultrasound-guided microwave ablation combined with camrelizumab for advanced primary liver cancer [J]. Chinese Hepatolgy, 2024, 29(12): 1493-1497.
[6]	ZHANG Zi-qiang, CHEN Kai-rong, WU Jun, LIU Jin-long, MA Feng. Relationship between serum miR-15b-5p and miR-145 and poor prognosis after TACE treatment in patients with primary liver cancer [J]. Chinese Hepatolgy, 2024, 29(12): 1503-1507.
[7]	CHENG Ming-liang, CHEN Jun-lin, LIU Xiao-jun, SUN Qiu, CHEN Jiang. Clinical analysis of hepatic arterial infusion chemotherapy combined with cindilizumab and bevacizumab injection in patients with unresectable primary liver cancer [J]. Chinese Hepatolgy, 2024, 29(11): 1358-1361.
[8]	ZHANG Yong-hong, SHEN Yu-chneg, LU Ying-ying, CHEN Guo-dong. Evaluation value of HIF-1, AFP-L3 and sPD-L1 in patients with primary liver cancer and the efficacy of TACE combined with sorafenib [J]. Chinese Hepatolgy, 2024, 29(11): 1368-1373.
[9]	LI Ming, JIANG Zhu-chun, SHI Yong-gang, DONG Shi-liang, HE Zi-huai, PAN Mei-fang. Evaluation of the therapeutic effect of transcatheter hepatic artery chemoembolization combined with large segment three-dimensional conformal radiotherapy on unresectable primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(9): 1079-1083.
[10]	LI Jiao-jiao, ZHAO Yong-chang, WU Jun-xia. The T lymphocyte and NK cell levels in patients with malignant pleural effusion after radical resection of primary hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 924-927.
[11]	WANG Chun-hong, FENG Wei-wei, ZHANG Jing, SI Chen-fei. A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy [J]. Chinese Hepatolgy, 2023, 28(8): 928-931.
[12]	XU Zheng-ju, LIU Hui-guo, YAN Yan-yan, YE Qiao-xia, ZHANG Xiao-man, HUANG Jin-fa, LI Yong-fei, WU Jin-piao. Effect of microwave ablation on serum levels of Golgi protein 73 and alpha fetoprotein in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(5): 554-558.
[13]	ZHU Ye-chen, GENG Cheng-jun, YIN Hui-kang, LI Ya-nan, FENG Quan-ye. The application of three-dimensional reconstruction in the evaluation of vascular system of primary liver cancer before TACE intervention [J]. Chinese Hepatolgy, 2023, 28(5): 559-563.
[14]	QIN Xiao-ping, ZHANG Jing, AI Ping. The expression of TREM-1, sCD163 and sB7-H3 in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(4): 461-464.
[15]	GUO Dan-dan, ZHANG Ying-hua, GAO Wen-feng, SHENG Shou-peng, ZHANG Yong-hong. Clinical features of primary liver cancer associated with Wilson's disease [J]. Chinese Hepatolgy, 2023, 28(3): 290-292.